



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

6/28/03
Patent
RECEIVED
JAN 24 2003
TECH CENTER 1600/2000

Applicant : Soumya Sahoo, et al.

Serial No. : 10/021,667

Case 20768

Art Unit:
1626
Examiner:
Taofiq A.
Solola

Filed : October 29, 2001

For : BENZOPYRANCARBOXIC ACID
DERIVATIVES FOR THE TREATMENT OF
DIABETES AND LIPID DISORDERS

Assistant Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

The citations listed on Form PTO-1449 are being submitted under the provisions of 37 CFR 1.56 and 1.97 in order to comply with the applicants' duty of disclosure. Their inclusion herein shall not be construed as an admission that the cited references are effective prior art or that they disclose or render obvious any aspect of the claimed invention. The references were cited in the International Search Report for the counterpart PCT Application. A copy of the Search Report and the cited patent applications are enclosed.

Applicants submit that the references listed on Form PTO 1449 taken alone or in any reasonable combination with previously cited references neither anticipate nor render obvious the present invention. It is respectfully requested that the Examiner initial and return the enclosed copy of Form PTO-1449 to evidence consideration of the disclosed references.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner of Patents and Trademarks, Washington, D.C.
20231, on the date appearing below.


MERCK & CO., INC.

By Jan. L. M. S. Date January 20, 2003

10/021,667
CASE #: 20768

The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement. Therefore, no fee is due. In the event that a fee is required in connection with this submission, the fee may be taken from Merck Deposit Account No. 13-2755.

The Examiner is invited to contact the attorney for applicant at the telephone number provided below if such would advance the prosecution of this application. Applicant respectfully requests early examination and Notice of Allowance.

By 
James L. McGinnis
Reg. No. 34,387
Attorney for Applicant

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-0641

Date: January 20, 2003